Truist initiated coverage on Dexcom with a new price target
$DXCM
Medical/Dental Instruments
Health Care
Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/12/2026 | $77.00 | Buy | The Benchmark Company |
| 3/24/2026 | $90.00 | In-line → Outperform | Evercore ISI |
| 1/12/2026 | $71.00 | Equal Weight → Underweight | Barclays |
| 12/2/2025 | $75.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/25/2025 | $68.00 | In-line | Evercore ISI |
| 10/21/2025 | $85.00 | Buy | Stifel |
| 9/8/2025 | Outperform → Perform | Oppenheimer | |
| 8/21/2025 | $100.00 | Buy | Argus |
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst
Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. Early access launch of a completely reimagined Stelo app will define a new era of glucose tracking for all people not on insulin seeking better health. Acquisition of Nutrisense will strengthen Dexcom's ability to provide personalized nutrition education and coaching to improve diabetes management and help further establish CGM as an effective tool for preventative care. DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforci
Company establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its techno
8-K - DEXCOM INC (0001093557) (Filer)
SD - DEXCOM INC (0001093557) (Filer)
144 - DEXCOM INC (0001093557) (Subject)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
The Benchmark Company initiated coverage of Dexcom with a rating of Buy and set a new price target of $77.00
Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00
Barclays downgraded Dexcom from Equal Weight to Underweight and set a new price target of $71.00
Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap Initiatives Follow Constructive Engagement with Elliott Management DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. "We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosen
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025. F
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)